Shanghai Runda Medical plans 2026 shareholder meeting on key proposals

Shanghai Runda Medical Technology will hold its first extraordinary general meeting of shareholders in 2026 on January 6, 2026, with an online voting period from 9:15 to 15:00 and a physical meeting at 13:30. The agenda includes the approval of a new compensation management system for directors and senior management, which will replace the previous 2023 version. This system, aligned with company performance and market standards, will dictate remuneration, with performance-based compensation making up at least 50% of the total.

Shareholders will also vote on the anticipated related-party transactions for 2026. The company forecasts significant transactions, including purchasing goods totaling 22,500.00 yuan and selling goods amounting to 56,100.00 yuan with various associated entities. These transactions are crucial for the company's daily operations and are expected to maintain fair pricing, with no material impact on the company's independence or profitability.

Additionally, the meeting will feature the election of six non-independent directors and four independent directors for the sixth board, following the expiration of the current board's term. The nominated non-independent directors include Zhang Chengxu, Liu Hui, Hu Zhenning, Chen Mo, Zhao Bin, and Yao Shenjie. Independent director candidates are Wang Jingjing, Jin Ying, Zhu Mingwei, and Chan Hwang Tong. These elections are critical for shaping the company's future leadership and strategic direction.